Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated …
Over the last 12 months, insiders at Rafael Holdings, Inc. have bought $0 and sold $0 worth of Rafael Holdings, Inc. stock.
On average, over the past 5 years, insiders at Rafael Holdings, Inc. have bought $11.06M and sold $449,542 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,451,612 shares for transaction amount of $12M was made by JONAS HOWARD S (Executive Chairman) on 2022‑07‑06.
2022-08-09 | Sale | Executive Chairman | 64,674 0.284% | $1.84 | $118,948 | +10.44% | ||
2022-08-08 | Sale | Executive Chairman | 14,787 0.0639% | $1.94 | $28,678 | +3.08% | ||
2022-08-05 | Sale | Executive Chairman | 97,774 0.4119% | $1.87 | $182,967 | +4.15% | ||
2022-08-05 | Sale | 64,674 0.2678% | $1.84 | $118,948 | +4.15% | |||
2022-07-06 | Executive Chairman | 6.45M 31.6178% | $1.86 | $12M | +4.17% | |||
2021-08-24 | Chief Executive Officer | 225,122 1.3289% | $44.92 | $10.11M | -91.70% |
JONAS HOWARD S | Executive Chairman | 3225806 13.5655% | $1.91 | 2 | 3 | +4.17% |
The Vanguard Group | $1.21M | 2.87 | 705,025 | +22.69% | +$224,250.16 | <0.0001 | |
Dimensional Fund Advisors | $593,462.00 | 1.4 | 345,036 | -6.1% | -$38,526.29 | <0.0001 | |
Kahn Brothers Group Inc | $464,734.00 | 1.1 | 270,363 | -0.63% | -$2,927.33 | 0.07 | |
Acuitas Investments, LLC | $451,890.00 | 1.07 | 262,727 | -18.5% | -$102,589.30 | 0.24 | |
BlackRock | $328,415.00 | 0.78 | 190,939 | -0.41% | -$1,334.72 | <0.0001 |